<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000Res</journal-id><journal-id journal-id-type="iso-abbrev">F1000Res</journal-id><journal-id journal-id-type="pmc-domain-id">2005</journal-id><journal-id journal-id-type="pmc-domain">f1000res</journal-id><journal-title-group><journal-title>F1000Research</journal-title></journal-title-group><issn pub-type="epub">2046-1402</issn><publisher><publisher-name>Faculty of 1000 Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7194457</article-id><article-id pub-id-type="pmcid-ver">PMC7194457.1</article-id><article-id pub-id-type="pmcaid">7194457</article-id><article-id pub-id-type="pmcaiid">7194457</article-id><article-id pub-id-type="pmid">32399189</article-id><article-id pub-id-type="doi">10.12688/f1000research.22143.1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Malaria vaccines: facing unknowns</article-title><fn-group content-type="pub-status"><fn><p>[version 1; peer review: 2 approved]</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Palacpac</surname><given-names initials="NMQ">Nirianne Marie Q.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#8211; Original Draft Preparation</role><role content-type="http://credit.casrai.org/">Writing &#8211; Review &amp; Editing</role><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4098-3972</contrib-id><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Horii</surname><given-names initials="T">Toshihiro</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#8211; Original Draft Preparation</role><role content-type="http://credit.casrai.org/">Writing &#8211; Review &amp; Editing</role><xref ref-type="aff" rid="a1">1</xref></contrib><aff id="a1">
<label>1</label>Department of Malaria Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:nirian@biken.osaka-u.ac.jp">nirian@biken.osaka-u.ac.jp</email></corresp><fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">349228</issue-id><elocation-id>F1000 Faculty Rev-296</elocation-id><history><date date-type="accepted"><day>21</day><month>4</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>04</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>11</day><month>05</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-05-15 00:37:18.520"><day>15</day><month>05</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2020 Palacpac NMQ and Horii T</copyright-statement><copyright-year>2020</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="f1000research-9-24419.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="f1000research-9-24419.pdf"/><abstract><p>Much of the gain in malaria control, in terms of regional achievements in restricting geographical spread and reducing malaria cases and deaths, can be attributed to large-scale deployment of antimalarial drugs, insecticide-treated bed nets, and early diagnostics. However, despite impressive progress, control efforts have stalled because of logistics, unsustainable delivery, or short-term effectiveness of existing interventions or a combination of these reasons. A highly efficacious malaria vaccine as an additional tool would go a long way, but success in the development of this important intervention remains elusive. Moreover, most of the vaccine candidate antigens that were investigated in early-stage clinical trials, selected partly because of their immunogenicity and abundance during natural malaria infection, were polymorphic or structurally complex or both. Likewise, we have a limited understanding of immune mechanisms that confer protection. We reflect on some considerable technological and scientific progress that has been achieved and the lessons learned.</p></abstract><kwd-group kwd-group-type="author"><kwd>malaria</kwd><kwd>vaccine</kwd><kwd>Plasmodium</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta><notes><sec sec-type="editor-note"><title>Editorial Note on the Review Process</title><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://f1000research.com/browse/f1000-faculty-reviews">F1000 Faculty Reviews</ext-link> are commissioned from members of the prestigious
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty">F1000 Faculty</ext-link> and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).</p><p>The referees who approved this article are: </p><list list-type="simple" list-content="reviewer-list"><list-item><p>
<named-content content-type="reviewer-name">Peter Kremsner</named-content>, University of T&#252;bingen, T&#252;bingen, Germany
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p></list-item><list-item><p>
<named-content content-type="reviewer-name">Patrick E Duffy</named-content>, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p></list-item></list></sec></notes></front><body><sec sec-type="intro"><title>Introduction</title><p>
<italic toggle="yes">Plasmodium</italic> protozoan parasites
<italic toggle="yes">P. falciparum</italic>,
<italic toggle="yes">P. vivax</italic>,
<italic toggle="yes">P. ovale</italic> (
<italic toggle="yes">P. ovale curtisi</italic> and
<italic toggle="yes">P. ovale wallikeri</italic>),
<italic toggle="yes">P. malariae</italic>, and
<italic toggle="yes">P. knowlesi</italic> can infect humans.
<italic toggle="yes">P. falciparum</italic> is responsible for the majority of malaria-attributable deaths, and the global malaria burden is borne disproportionally by children in sub-Saharan Africa
<sup><xref rid="ref-1" ref-type="bibr">1</xref></sup>. Malaria symptoms range from severe headaches, chills, joint pain, and fever-like symptoms to red blood cell dysregulation and lysis that can lead to severe anemia, sequestration of infected red blood cells, or occlusion. Occlusion can lead to cerebral malaria or complications associated with placental malaria, including adverse birth outcomes with long-term sequelae or death.</p><p>Vaccines for malaria aim to either eliminate/prevent infection (for example, in the liver or blood or they interrupt transmission in mosquitoes) or control/limit parasite growth/multiplication and duration of infection
<sup><xref rid="ref-2" ref-type="bibr">2</xref></sup>. Approaches to malaria vaccine development have ranged from traditional (live-attenuated or killed) to subunit (single-antigen recombinant proteins that target the various stages in the parasite life cycle) vaccines to newer approaches targeting the inclusion of only defined antigenic regions or critical epitopes
<sup><xref rid="ref-2" ref-type="bibr">2</xref>&#8211;
<xref rid="ref-4" ref-type="bibr">4</xref></sup>. The struggle continues to develop a vaccine to protect people from this disease.</p></sec><sec><title>Burden and current interventions</title><p>More than 90% of the sub-Saharan Africa population live in malaria-endemic areas
<sup><xref rid="ref-1" ref-type="bibr">1</xref>,
<xref rid="ref-5" ref-type="bibr">5</xref></sup>. In Africa, 99.7% of estimated malaria cases are due to
<italic toggle="yes">P. falciparum</italic>
<sup><xref rid="ref-1" ref-type="bibr">1</xref></sup>. Outside of Africa,
<italic toggle="yes">P. vivax</italic> accounts for most of the disease burden: 73% in the World Health Organization (WHO) Region of the Americas and 53% in the WHO Southeast Asia Region
<sup><xref rid="ref-1" ref-type="bibr">1</xref></sup>.
<italic toggle="yes">P. vivax</italic> burden is difficult to assess as infections can cause relapse months or years after initial infection because of the persistence of hypnozoites in hepatocytes. Other species represent a small proportion globally.
<italic toggle="yes">P. ovale</italic> and
<italic toggle="yes">P. malariae</italic> are common sympatric species in malaria-endemic regions
<sup><xref rid="ref-6" ref-type="bibr">6</xref>,
<xref rid="ref-7" ref-type="bibr">7</xref></sup>. Data on the global burden of
<italic toggle="yes">P. knowlesi</italic>, a zoonotic parasite, are much less known. Nevertheless, this species has been reported to cause severe human malaria and is important for certain populations in Indonesia, the Philippines, Cambodia, South Thailand, South Myanmar, and South Vietnam
<sup><xref rid="ref-8" ref-type="bibr">8</xref>&#8211;
<xref rid="ref-10" ref-type="bibr">10</xref></sup>.</p><p>The WHO World Malaria Report
<sup><xref rid="ref-1" ref-type="bibr">1</xref></sup> and high-resolution maps for
<italic toggle="yes">P. falciparum</italic>
<sup><xref rid="ref-5" ref-type="bibr">5</xref></sup> and
<italic toggle="yes">P. vivax</italic>
<sup><xref rid="ref-11" ref-type="bibr">11</xref></sup> capture the considerable progress in reducing malaria burden and the stall in the rates of decline in recent years. In a handful of developed countries, control efforts were aided greatly by successful economic development, improved health-care systems, and urbanization
<sup><xref rid="ref-5" ref-type="bibr">5</xref></sup>. But in resource-poor settings, gains achieved are noted as fragile, relying on a limited number of interventions: insecticide-treated bed nets, indoor residual spraying, artemisinin combination therapy, intermittent preventive treatment, and increased access to diagnostic testing
<sup><xref rid="ref-12" ref-type="bibr">12</xref></sup>. Moreover, bottlenecks and gaps for optimal coverage exist because of less sensitive tools and infection/disease management; for example, pregnant women are possible reservoirs that sustain malaria transmission, and pyrimethamine is contraindicated in the first trimester
<sup><xref rid="ref-13" ref-type="bibr">13</xref>,
<xref rid="ref-14" ref-type="bibr">14</xref></sup>. The campaign for increased annual funding, from US $2.7 billion to US $6.4 billion, for investments that aimed to meet a 40% reduction in malaria incidence and mortality rates remains challenging
<sup><xref rid="ref-15" ref-type="bibr">15</xref></sup>. For vector control, four commonly used insecticide classes are already in widespread use in Africa, the Americas, Southeast Asia, the Eastern Mediterranean, and the Western Pacific, raising warning bells for a possible emergence of insecticide resistance
<sup><xref rid="ref-12" ref-type="bibr">12</xref></sup>. The same is true for antimalarial drugs. At present, there are only three major/broad categories of available antimalarials. Poor quality, incomplete treatment, and misuse (including continued use of artemisinin-based monotherapy) could result to development and spread of drug-resistant parasites. Fortunately, to date, no evidence for substantial drug resistance has been documented
<sup><xref rid="ref-16" ref-type="bibr">16</xref>&#8211;
<xref rid="ref-18" ref-type="bibr">18</xref></sup>. However, the Global Technical Strategy for Malaria 2016&#8211;2030 milestones
<sup><xref rid="ref-15" ref-type="bibr">15</xref></sup>, to reduce malaria incidence and mortality by at least 40% in 2020, cannot be attained with current tools.</p></sec><sec><title>Malaria vaccines</title><p>By experience, vaccines are among the most successful and cost-effective public health tools. Millions of lives have been saved and a substantial reduction in morbidity has been associated with vaccine scale-up implementation against other diseases. A case in point would be the recent vaccine implementation of meningococcal vaccine in sub-Saharan Africa
<sup><xref rid="ref-19" ref-type="bibr">19</xref></sup>. A malaria vaccine, if implemented through the routine/existing immunization delivery programmes, such as the Expanded Programme on Immunization (EPI), could have more reaching coverage logistically and improved compliance (compared with traditional antimalarial prophylaxis) and would help close the gap left by other control measures. However, considerations for inclusion to the EPI also need validation in field trials. Co-administration of a candidate tuberculosis vaccine, MVA85A, with EPI vaccines resulted in lowered tuberculosis-specific immunogenicity
<sup><xref rid="ref-20" ref-type="bibr">20</xref></sup>. On the other hand, with the pre-erythrocytic malaria vaccine&#8212;chimpanzee adenovirus 63 and modified vaccinia virus Ankara encoding multiple epitope string thrombospondin-related adhesion protein (ChAd63 MVA ME-TRAP)&#8212;antibody responses to EPI vaccines were not altered in a phase Ib trial
<sup><xref rid="ref-21" ref-type="bibr">21</xref></sup>. Both studies underscore the importance of optimal schedules and timing of immunizations for testing in clinical trials as well as for actual vaccine implementation.</p><p>A number of vaccines in the malaria pipeline have similar challenges/limitations due in part to the complex biology and life cycle of
<italic toggle="yes">Plasmodium</italic> and the immunological interplay between the parasite and host. At the same time, every malaria infection can be considered unique in terms of antigenic repertoire and host, frequency of exposure, age, access to treatment, and presence of co-morbidities. Three recent reviews summarize vaccines now in development
<sup><xref rid="ref-2" ref-type="bibr">2</xref>&#8211;
<xref rid="ref-4" ref-type="bibr">4</xref></sup>. RTS,S (registered as Mosquirix), based on the circumsporozoite protein, is thus far the only vaccine that has progressed beyond phase 3 and is now in a WHO-recommended and -sponsored pilot implementation program complementing a GlaxoSmithKline-sponsored phase 4 trial
<sup><xref rid="ref-2" ref-type="bibr">2</xref></sup>. RTS,S is a pre-erythrocytic vaccine directed at the sporozoite stage or at the infected hepatocyte. The vaccine, in theory, should prevent blood-stage infection but, in reality, proved to be &#8220;leaky&#8221;
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. The pilot implementation of RTS,S aims (a) to address whether the protection demonstrated in the 5- to 17-month old multicenter phase 3 trial can be replicated in the context of routine health systems with a four-dose schedule and to evaluate (b) the excess risk of febrile seizures observed within 7 days after a vaccine dose, (c) the number of meningitis cases, (d) the number of cerebral malaria cases in the malaria vaccine group compared with the control, and (e) the imbalance of mortality among girls who received the vaccine
<sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>. The Joint Technical Expert Group (JTEG) on malaria vaccines also recommended monitoring the emergence of vaccine resistance strains and testing of alternative schedules and other strategies to improve the efficacy of RTS,S. The JTEG noted that, if safety concerns are resolved and favorable implementation data become available, the WHO can recommend country-wide introduction. Projection for RTS,S shows that if it is implemented in all 43 malaria-endemic countries in sub-Saharan Africa, 123 million (95% prediction interval, 117 to 129 million) malaria episodes over the first 10 years could be averted
<sup><xref rid="ref-24" ref-type="bibr">24</xref></sup>.</p><p>Indeed, the RTS,S experience is a learning curve for all other malaria vaccines in the pipeline. Of note, the concern about a possible negative effect on overall female mortality may indeed be valid and needs careful consideration since this finding was observed in both age groups
<sup><xref rid="ref-25" ref-type="bibr">25</xref></sup> and in a number of vaccines
<sup><xref rid="ref-26" ref-type="bibr">26</xref>,
<xref rid="ref-27" ref-type="bibr">27</xref></sup>. Similar obstacles and lessons provide much hope, rather than pessimism, as we move forward in addressing some key challenges.</p></sec><sec><title>Polymorphism</title><p>As in other vaccine candidates, polymorphism abrogates antigen recognition. On the other hand, conserved important epitopes are generally poorly immunogenic. In RTS,S, the dominant epitope recognized by antibodies&#8212;(NANP)n from the circumsporozoite protein (CSP)&#8212;is totally conserved in
<italic toggle="yes">P. falciparum</italic> but the T-cell (as well as B-cell) epitopes are known to be polymorphic
<sup><xref rid="ref-2" ref-type="bibr">2</xref>,
<xref rid="ref-3" ref-type="bibr">3</xref></sup>. A number of other vaccine candidates did not show much promise after efficacy trials suggested strain-specific protection
<sup><xref rid="ref-2" ref-type="bibr">2</xref>&#8211;
<xref rid="ref-4" ref-type="bibr">4</xref></sup>. In fact, the lack of success in developing subunit blood-stage vaccine candidates and lack of cross-stage immunity were among the driving factors to develop whole parasite vaccines (WPVs). WPV supposes that no individual parasite protein can be sufficient to induce strain-transcending immunity and that, aside from antibodies, B and T cells also play a role. WPVs aimed to maximize antigen breadth, although, whether irradiated parasites, genetically attenuated parasites, chemically attenuated parasites or killed parasites, the vaccine pathway represents a significant challenge because of difficulties in vaccine manufacture and specific regulatory issues
<sup><xref rid="ref-28" ref-type="bibr">28</xref></sup>. So far, clinical trials have shown that WPVs are well tolerated in terms of reactogenicity
<sup><xref rid="ref-2" ref-type="bibr">2</xref></sup>. The presence of extraneous (possible toxins, pathogens, and contaminants) materials not essential for the generation of protective immune response as well as concerns on vaccine route, dose, and regimen are being addressed
<sup><xref rid="ref-2" ref-type="bibr">2</xref>,
<xref rid="ref-3" ref-type="bibr">3</xref>,
<xref rid="ref-28" ref-type="bibr">28</xref></sup>.</p><p>Other innovations in antigen discovery have now come up with an extensive list of potential antigens from genomic-, proteomic-, and transcriptomic-based approaches
<sup><xref rid="ref-29" ref-type="bibr">29</xref>&#8211;
<xref rid="ref-32" ref-type="bibr">32</xref></sup>. Similar to vaccine development against viral infections such as human immunodeficiency virus and influenza, structure-guided vaccine design is currently tapped to identify protective/functional and non-functional epitopes in antigen&#8211;antibody complexes
<sup><xref rid="ref-33" ref-type="bibr">33</xref>&#8211;
<xref rid="ref-35" ref-type="bibr">36</xref></sup>. With difficulties for representative
<italic toggle="yes">in vitro</italic> models, structure-guided vaccine design has also been used to inform the development of at least the most promising vaccine candidate for
<italic toggle="yes">P. vivax</italic>, the
<italic toggle="yes">Pv</italic> Duffy-binding protein
<sup><xref rid="ref-37" ref-type="bibr">37</xref>,
<xref rid="ref-38" ref-type="bibr">38</xref></sup>.</p><p>These innovations have, likewise, pushed antigen delivery platforms. Since subunit vaccines based on soluble recombinant proteins are often poorly immunogenic, the use of virus capsid-like particle vaccine platforms is beginning in the malaria field
<sup><xref rid="ref-39" ref-type="bibr">39</xref>,
<xref rid="ref-40" ref-type="bibr">40</xref></sup>. Virus-like particles (VLPs), when overexpressed, spontaneously self-assemble into particles that are highly immunogenic because of their structural resemblance to original live viruses
<sup><xref rid="ref-39" ref-type="bibr">39</xref>&#8211;
<xref rid="ref-43" ref-type="bibr">43</xref></sup>. A direct comparison of three VLP platforms for a transmission-blocking vaccine
<sup><xref rid="ref-44" ref-type="bibr">44</xref></sup> showed that high quantity and quality of antibodies with minimal reactogenicity could be achieved.</p></sec><sec><title>Poor understanding of vaccine-induced immune response</title><p>To date, we still have a considerable lack of understanding in the immunological mechanisms that provide protection against malaria, including what immune responses are induced in people who are protected and in people who are not. Immune correlates of protection are known to exist for successful vaccines. This knowledge can permit licensure of new vaccine formulations or extension of vaccine indications to new populations on the basis of immunogenicity endpoints
<sup><xref rid="ref-45" ref-type="bibr">45</xref>,
<xref rid="ref-46" ref-type="bibr">46</xref></sup>. In some cases, evaluations are restricted to antibody titers and a few basic T-cell analyses: cytokine-ELISpot or interferon-gamma, interleukin-2 (IL-2), or tumor necrosis factor-alpha (TNF&#945;) readouts or a combination of these. Hepatitis B vaccine testing was simplified when it was shown that hepatitis B S antigen antibodies of more than 10 mIU/mL were surrogate markers of protection
<sup><xref rid="ref-47" ref-type="bibr">47</xref>,
<xref rid="ref-48" ref-type="bibr">48</xref></sup>. Interestingly, a recent study also showed the utility of T-cell (TNF&#945;, IL-10, or IL-6) responses 32 years after vaccination despite the absence of detectable anti-hepatitis B antibodies
<sup><xref rid="ref-49" ref-type="bibr">49</xref></sup>. The cellular responses provided insight on how to evaluate long-term immunity; even under natural exposure, no breakthrough hepatitis B virus (HBV) infection was recorded
<sup><xref rid="ref-49" ref-type="bibr">49</xref></sup>, suggesting that the immune response can be boosted to prevent acute illness and chronic HBV infection.</p><p>In malaria, antibody titers and T-cell responses showed limited correlation and have largely failed to predict vaccine efficacy (VE) or down-select vaccine formulations prior to late-stage, large trials
<sup><xref rid="ref-50" ref-type="bibr">50</xref></sup>. In RTS,S, antibody titer concentrations of 121 enzyme-linked immunosorbent assay units per milliliter (95% confidence interval [CI] 98&#8211;153) prevented 50% of infection, but no threshold level for protection was found in the phase 3 trial
<sup><xref rid="ref-51" ref-type="bibr">51</xref></sup>. Further review of previous trials also showed that a modification of dose and schedule improved vaccine protection: 62% of volunteers (10/16) given the full dose at the standard 0-, 1-, 2-month regimen were protected 3 weeks after the last vaccination, whereas 86% of volunteers (26/30) were protected when the third dose occurred 6 months after the second and the dose was reduced to one fifth of the original dose (known as fractional dosing
<sup><xref rid="ref-52" ref-type="bibr">52</xref></sup>). With a fractional dose, titers of anti-NANP antibody were similar to subjects vaccinated using standard regimen, and it was speculated that the altered dosing had an effect on antibody avidity, somatic hypermutation, and isotype switching
<sup><xref rid="ref-52" ref-type="bibr">52</xref>,
<xref rid="ref-53" ref-type="bibr">53</xref></sup>. The roles of CD4
<sup>+</sup> T-cell responses have been suggested but remained inconsistent
<sup><xref rid="ref-54" ref-type="bibr">54</xref>,
<xref rid="ref-55" ref-type="bibr">55</xref></sup>, although it cannot be denied that protection is indeed mediated by complex immune functions. The inability to maintain high antibody titer after vaccination also needs in-depth studies
<sup><xref rid="ref-51" ref-type="bibr">51</xref></sup>. Waning or duration of immunity remains an important question as current vaccine candidates still have to demonstrate an acceptable duration of protection so that frequent revaccination is not necessary.</p><p>Besides antibody responses, CD4 and T cells have also been implicated in the WPV, PfSPZ
<sup><xref rid="ref-56" ref-type="bibr">56</xref></sup>. The absence of a T-cell response in 6- to 11-month-old vaccinees was interpreted to mean that there will be no protection for this age group by using the current PfSPZ immunization regimen (three doses at 8-week intervals). For blood-stage vaccine GMZ2/alum, a phase 2 efficacy trial showed higher VE in children 3 to 4 years old (VE = 20%, 95% CI 4&#8211;33%) than in children 1 to 2 years old (VE = 14%, 95% CI 3.6&#8211;23%)
<sup><xref rid="ref-57" ref-type="bibr">57</xref></sup>. It was concluded that, compared with toddlers, the older children have antibodies that were more functionally competent in terms of avidity and IgG subclass profile. Acquired background immunity to malaria would have helped the older cohort.</p><p>There is general agreement that effective assessment of induced immune response needs unbiased, comprehensive profiling together with mathematical modelling/computational analyses. Such methods can capture the overall picture/combination effects of multiple immune responses
<sup><xref rid="ref-45" ref-type="bibr">45</xref>,
<xref rid="ref-58" ref-type="bibr">58</xref>,
<xref rid="ref-59" ref-type="bibr">59</xref></sup>. Robust screening assays to assess protective potential or detect non-direct inhibitory or neutralizing activity of antibodies or assays that capture antibody-complement interactions and their consequences to parasite function and viability are most important considerations. For meningococcal vaccines, the availability of the serum bactericidal antibody assay, which measures complement-mediated killing via functional antibody concentrations, has proven to be a valuable tool
<sup><xref rid="ref-60" ref-type="bibr">60</xref></sup>.</p></sec><sec><title>Controlled human malaria infection</title><p>The licensing by US Food and Drug Administration of a live, oral cholera vaccine (Vaxchora) for use in travelers on the basis of controlled human infection model in volunteers 18 to 64 years of age raised hopes that a malaria vaccine for travelers could also utilize human challenge data and pass along the same regulatory approach for licensure
<sup><xref rid="ref-61" ref-type="bibr">61</xref>,
<xref rid="ref-62" ref-type="bibr">62</xref></sup>. Clearly, controlled human malaria infection (CHMI) is a powerful tool (a) to provide early-stage proof-of-concept efficacy for vaccine candidates and (b) to address the limitation of preclinical testing in mice and non-human primates to predict immune response and to study mechanisms of protective immunity
<sup><xref rid="ref-63" ref-type="bibr">63</xref>,
<xref rid="ref-64" ref-type="bibr">64</xref></sup>. Because this experimental model allows some homogeneity/control of parasitemia within and between treatment arms, a major advantage is the relatively small sample size required for the evaluation of VE. The model is also ideally useful to advance field trials of transmission-blocking vaccines
<sup><xref rid="ref-65" ref-type="bibr">65</xref></sup>. In addition, it is less restrictive to have access to blood samples for antibody and T-cell work, allowing in-depth studies.</p><p>So far, only RTS,S
<sup><xref rid="ref-55" ref-type="bibr">55</xref></sup>, chemoattenuated
<italic toggle="yes">P. falciparum</italic> sporozoite vaccine
<sup><xref rid="ref-66" ref-type="bibr">66</xref></sup>, whole parasite immunization under chloroquine drug cover
<sup><xref rid="ref-67" ref-type="bibr">67</xref></sup>, and whole sporozoite radiation-attenuated vaccines
<sup><xref rid="ref-68" ref-type="bibr">68</xref></sup> were able to induce sterile immunity in a significant proportion of human volunteers. CHMI was used by RTS,S to test for various formulations, adjuvants, and vaccine timings
<sup><xref rid="ref-52" ref-type="bibr">52</xref>,
<xref rid="ref-55" ref-type="bibr">55</xref>,
<xref rid="ref-64" ref-type="bibr">64</xref></sup>. The
<italic toggle="yes">P. vivax</italic> CHMI model has been used successfully to test the efficacy of radiation-attenuated sporozoites administered by mosquito bite
<sup><xref rid="ref-69" ref-type="bibr">69</xref></sup>.</p><p>CHMI has been harnessed to identify the range and specificities of antibody responses and antigen targets
<sup><xref rid="ref-70" ref-type="bibr">70</xref></sup> as well as down-select other vaccine candidates
<sup><xref rid="ref-71" ref-type="bibr">71</xref></sup>. Currently, five challenge strains are available for CHMI use
<sup><xref rid="ref-72" ref-type="bibr">72</xref>&#8211;
<xref rid="ref-75" ref-type="bibr">75</xref></sup>. This is important, as it is necessary to address the regulatory concern of strain-transcending protective efficacy or cross-strain protection. All strains so far show global geographic differences in genetic variation
<sup><xref rid="ref-72" ref-type="bibr">72</xref>,
<xref rid="ref-73" ref-type="bibr">73</xref>,
<xref rid="ref-75" ref-type="bibr">75</xref></sup>; however, how representative they are of the overall diversity of
<italic toggle="yes">P. falciparum</italic> field population remains to be seen. Efforts are ongoing to increase familiarity on the restrictions and challenges of CHMI models to regulators to determine the feasibility to accept these trials as part of the regulatory package for licensure
<sup><xref rid="ref-63" ref-type="bibr">63</xref>,
<xref rid="ref-64" ref-type="bibr">64</xref>,
<xref rid="ref-76" ref-type="bibr">76</xref>,
<xref rid="ref-77" ref-type="bibr">77</xref></sup>.</p></sec><sec><title>Low-level parasite infection and immune tolerance</title><p>Low-level parasite infection confuse diagnostics/detection or attribution of symptom/fever to malaria and raise the question of how the chronic nature of malaria infection (persistent parasite infection) amplifies or down-regulates immune response. B-cell hypo-responsiveness as a result of meningococcal and polysaccharide vaccines has been reported
<sup><xref rid="ref-78" ref-type="bibr">78</xref></sup>. Many clinical trials suggest that pre-existing immunity induced immune tolerance, resulting in lower immunogenicity and efficacy in African adults and malaria-exposed children
<sup><xref rid="ref-79" ref-type="bibr">79</xref>&#8211;
<xref rid="ref-82" ref-type="bibr">82</xref></sup>. The picture becomes more complicated when host genetics, access to treatment, and co-infection are considered. Performing studies to assess these confounding/contributory variables in vaccine trials are needed.</p></sec><sec><title>Vaccine efficacy in clinical trials</title><p>Endpoints and assessment methods to measure VE in clinical trials also lack clear consensus. In malaria-endemic areas, the rate of acquisition of natural immunity will vary between individuals; even within a country, malaria parasite transmission differs per site depending on climate/season and breeding sites. These factors affect the clinical trial design, surveillance methods, follow-up, and size of cohort. With RTS,S, during clinical trials, VE was evaluated by measuring time to first infection since natural infection is present in malaria-endemic areas and there is no control of time or amount of exposure to malaria in the different subjects. However, the WHO/JTEG specifically requested that all vaccine efficacies be reported against all episodes of the outcome (not only first or only episode) to better reflect the public health contribution of the vaccine. And what about boosting? Boosting through natural infection appears to be an important contributor in reducing the multiplicity of malaria episodes, especially for the blood-stage vaccine, SE36
<sup><xref rid="ref-83" ref-type="bibr">83</xref></sup>. Of note, not all infections are clinically important (or manifest as clinical symptoms) and this complicates predictions for exposure, risk, and protective efficacy.</p><p>Vaccines aimed against malaria sporozoites might lead to a delayed acquisition of natural immunity, resulting in increased risk of malaria when the protection afforded by vaccination has waned compared with individuals who did not receive the vaccine. This was observed in other malaria interventions such as weekly malaria chemoprophylaxis and use of insecticide-treated bed nets. The phenomenon has been termed rebound malaria
<sup><xref rid="ref-84" ref-type="bibr">84</xref>,
<xref rid="ref-85" ref-type="bibr">85</xref></sup>. An additional three years of follow-up showed that RTS,S/AS01 vaccination might lead to periods of increased risk to uncomplicated malaria when vaccine-induced protection has waned
<sup><xref rid="ref-85" ref-type="bibr">85</xref></sup>. This observation is in line with the previous phase 2 study carried out in Kenya, where the initial protection provided by three RTS,S/AS01 doses was offset by rebound after five years in areas with higher-than-average exposure to malaria parasites
<sup><xref rid="ref-86" ref-type="bibr">86</xref></sup>. Three-year extension of the phase 3 trial in Nanoro, Burkina Faso showed an increase in clinical malaria incidence in the RTS,S vaccinees when the children were older. Nevertheless, the rebound was not outweighed by the initial benefit and there was no increased risk for severe malaria or a shift toward cerebral malaria
<sup><xref rid="ref-85" ref-type="bibr">85</xref></sup>.</p></sec><sec><title>Novel adjunctive tools</title><p>Another important question that research would want to address is how to achieve and maintain stronger and longer-lasting VE through the use of adjuvants or optimal dose/delivery methods or both. An appropriate adjuvant will greatly increase the immunogenicity of a vaccine
<sup><xref rid="ref-58" ref-type="bibr">58</xref>,
<xref rid="ref-87" ref-type="bibr">87</xref>&#8211;
<xref rid="ref-90" ref-type="bibr">90</xref></sup>. Vaccine adjuvants have been tapped to target innate immune responses, activate the Toll-like receptor signaling pathway, and expand the antibody repertoire against the malaria parasite. Studies for novel and more effective human-compatible adjuvant to improve vaccine response are ongoing.</p></sec><sec sec-type="conclusions"><title>Summary and Conclusions</title><p>Efforts to come up with efficacious malaria vaccine continue despite challenges. As new approaches (use of structural epitopes for antigen selection; development of novel vectors, adjuvants, and delivery methods; altered vaccine schedules and dosages; utilization of new tools) lend themselves to malaria research, a cooperative global effort should also be established to allow various vaccine candidates in the developmental pipeline to be compared side by side in proof-of-concept clinical trials to overcome most of the financial challenge in investing in large-scale good manufacturing practice (GMP) production, phase III and IV studies. It has become generally accepted that likely combinations of effective vaccines that complement each other will be used, and a successful vaccine must be able to induce both humoral and T-cell responses. But the efficacy of each vaccine component needs to be evaluated, or a hit-and-miss approach will entail extensive investment. The burden of developing a malaria vaccine is currently spread to only a few partners reluctant to invest as more candidates are discovered and innovations are made in delivery, yet there are knowledge gaps in the candidates&#8217; mechanism/correlates of protection and undefined regulatory pathway(s). A collaborative effort is especially important to be initiated from the scientific community given that primary target groups are those in low- and middle-income countries. Finally, as illustrated above, most available data come from studies of
<italic toggle="yes">P. falciparum</italic>, and studies on
<italic toggle="yes">P. vivax</italic> are also needed to help advance vaccines that will contribute to malaria elimination.</p></sec><sec><title>Acknowledgments</title><p>Authors thank their many collaborators&#8212;Sophie Houard and European Vaccine Initiative, Sodiomon B. Sirima and his team (Groupe de Recherche Action en Sant&#233;), Nobelpharma Co. Ltd.&#8212;for their ideas, motivation, and tenacity. An efficacious malaria vaccine can be achieved!</p></sec></body><back><ref-list><ref id="ref-1"><label>1</label><mixed-citation publication-type="journal"><collab>World Malaria Report 2019</collab>. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO.<year> 2019</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/world-malaria-report-2019">Reference Source</ext-link></mixed-citation></ref><ref id="ref-2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draper</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Sack</surname><given-names>BK</given-names></name><name name-style="western"><surname>King</surname><given-names>CR</given-names></name><etal/></person-group>:
<article-title>Malaria Vaccines: Recent Advances and New Horizons.</article-title><source><italic toggle="yes">Cell Host Microbe.</italic></source><year>2018</year>;<volume>24</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>56</lpage>.
<pub-id pub-id-type="doi">10.1016/j.chom.2018.06.008</pub-id><pub-id pub-id-type="pmid">30001524</pub-id><pub-id pub-id-type="pmcid">PMC6054918</pub-id></mixed-citation></ref><ref id="ref-3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><etal/></person-group>:
<article-title>Prospects for Malaria Vaccines: Pre-Erythrocytic Stages, Blood Stages, and Transmission-Blocking Stages.</article-title><source><italic toggle="yes">Biomed Res Int.</italic></source><year>2019</year>;<volume>2019</volume>:<fpage>9751471</fpage>.
<pub-id pub-id-type="doi">10.1155/2019/9751471</pub-id><pub-id pub-id-type="pmid">31687404</pub-id><pub-id pub-id-type="pmcid">PMC6794966</pub-id></mixed-citation></ref><ref id="ref-4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salamanca</surname><given-names>DR</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>M</given-names></name><name name-style="western"><surname>Camargo</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>
<italic toggle="yes">Plasmodium falciparum</italic> Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines.</article-title><source><italic toggle="yes">Front Microbiol.</italic></source><year>2019</year>;<volume>10</volume>:<fpage>2712</fpage>.
<pub-id pub-id-type="doi">10.3389/fmicb.2019.02712</pub-id><pub-id pub-id-type="pmid">31849871</pub-id><pub-id pub-id-type="pmcid">PMC6901501</pub-id></mixed-citation></ref><ref id="ref-5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>TCD</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Mapping the global prevalence, incidence, and mortality of
<italic toggle="yes">Plasmodium falciparum</italic>, 2000-17: a spatial and temporal modelling study.</article-title><source><italic toggle="yes">Lancet.</italic></source><year>2019</year>;<volume>394</volume>(<issue>10195</issue>):<fpage>322</fpage>&#8211;<lpage>31</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(19)31097-9</pub-id><pub-id pub-id-type="pmid">31229234</pub-id><pub-id pub-id-type="pmcid">PMC6675740</pub-id></mixed-citation></ref><ref id="ref-6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yman</surname><given-names>V</given-names></name><name name-style="western"><surname>Wandell</surname><given-names>G</given-names></name><name name-style="western"><surname>Mutemi</surname><given-names>DD</given-names></name><etal/></person-group>:
<article-title>Persistent transmission of
<italic toggle="yes">Plasmodium malariae</italic> and
<italic toggle="yes">Plasmodium ovale</italic> species in an area of declining
<italic toggle="yes">Plasmodium falciparum</italic> transmission in eastern Tanzania.</article-title><source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source><year>2019</year>;<volume>13</volume>(<issue>5</issue>):<fpage>e0007414</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0007414</pub-id><pub-id pub-id-type="pmid">31136585</pub-id><pub-id pub-id-type="pmcid">PMC6555537</pub-id></mixed-citation></ref><ref id="ref-7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rutledge</surname><given-names>GG</given-names></name><name name-style="western"><surname>B&#246;hme</surname><given-names>U</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>
<italic toggle="yes">Plasmodium malariae</italic> and
<italic toggle="yes">P. ovale</italic> genomes provide insights into malaria parasite evolution.</article-title><source><italic toggle="yes">Nature.</italic></source><year>2017</year>;<volume>542</volume>(<issue>7639</issue>):<fpage>101</fpage>&#8211;<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1038/nature21038</pub-id><pub-id pub-id-type="pmid">28117441</pub-id><pub-id pub-id-type="pmcid">PMC5326575</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/727237188">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyes</surname><given-names>CL</given-names></name><name name-style="western"><surname>Henry</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Golding</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Defining the geographical range of the
<italic toggle="yes">Plasmodium knowlesi</italic> reservoir.</article-title><source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source><year>2014</year>;<volume>8</volume>(<issue>3</issue>):<fpage>e2780</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0002780</pub-id><pub-id pub-id-type="pmid">24676231</pub-id><pub-id pub-id-type="pmcid">PMC3967999</pub-id></mixed-citation></ref><ref id="ref-9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>B</given-names></name><name name-style="western"><surname>Daneshvar</surname><given-names>C</given-names></name></person-group>:
<article-title>Human infections and detection of
<italic toggle="yes">Plasmodium knowlesi</italic>.</article-title><source><italic toggle="yes">Clin Microbiol Rev.</italic></source><year>2013</year>;<volume>26</volume>(<issue>2</issue>):<fpage>165</fpage>&#8211;<lpage>84</lpage>.
<pub-id pub-id-type="doi">10.1128/CMR.00079-12</pub-id><pub-id pub-id-type="pmid">23554413</pub-id><pub-id pub-id-type="pmcid">PMC3623376</pub-id></mixed-citation></ref><ref id="ref-10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fornace</surname><given-names>KM</given-names></name><name name-style="western"><surname>Brock</surname><given-names>PM</given-names></name><name name-style="western"><surname>Abidin</surname><given-names>TR</given-names></name><etal/></person-group>:
<article-title>Environmental risk factors and exposure to the zoonotic malaria parasite
<italic toggle="yes">Plasmodium knowlesi</italic> across northern Sabah, Malaysia: a population-based cross-sectional survey.</article-title><source><italic toggle="yes">The Lancet Planetary Health.</italic></source><year>2019</year>;<volume>3</volume>(<issue>4</issue>):<fpage>e179</fpage>&#8211;<lpage>e186</lpage>.
<pub-id pub-id-type="doi">10.1016/S2542-5196(19)30045-2</pub-id><pub-id pub-id-type="pmid">31029229</pub-id><pub-id pub-id-type="pmcid">PMC6484808</pub-id></mixed-citation></ref><ref id="ref-11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battle</surname><given-names>KE</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>TCD</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Mapping the global endemicity and clinical burden of
<italic toggle="yes">Plasmodium vivax</italic>, 2000&#8211;17: a spatial and temporal modelling study.</article-title><source><italic toggle="yes">Lancet.</italic></source><year>2019</year>;<volume>394</volume>(<issue>10195</issue>):<fpage>332</fpage>&#8211;<lpage>343</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(19)31096-7</pub-id><pub-id pub-id-type="pmid">31229233</pub-id><pub-id pub-id-type="pmcid">PMC6675736</pub-id></mixed-citation></ref><ref id="ref-12"><label>12</label><mixed-citation publication-type="journal"><collab>Compendium of WHO malaria guidance &#8211; prevention, diagnosis, treatment, surveillance and elimination</collab>: Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO.<year>2019</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/malaria/publications/atoz/compendium/en/">Reference Source</ext-link></mixed-citation></ref><ref id="ref-13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>KA</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Scoullar</surname><given-names>MJL</given-names></name><etal/></person-group>:
<article-title>Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis.</article-title><source><italic toggle="yes">Lancet Glob Health.</italic></source><year>2017</year>;<volume>5</volume>(<issue>11</issue>):<fpage>e1101</fpage>&#8211;<lpage>e1112</lpage>.
<pub-id pub-id-type="doi">10.1016/S2214-109X(17)30340-6</pub-id><pub-id pub-id-type="pmid">28967610</pub-id></mixed-citation></ref><ref id="ref-14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogerson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Desai</surname><given-names>M</given-names></name><name name-style="western"><surname>Mayor</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem.</article-title><source><italic toggle="yes">Lancet Infect Dis.</italic></source><year>2018</year>;<volume>18</volume>(<issue>4</issue>):<fpage>e107</fpage>&#8211;<lpage>e118</lpage>.
<pub-id pub-id-type="doi">10.1016/S1473-3099(18)30066-5</pub-id><pub-id pub-id-type="pmid">29396010</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/732604977">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-15"><label>15</label><mixed-citation publication-type="journal"><collab>World Health Organization</collab>:
<article-title>Global technical strategy for malaria 2016-2030</article-title>. World Health Organization.<year>2015&#8206;</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/malaria/publications/atoz/9789241564991/en/">Reference Source</ext-link></mixed-citation></ref><ref id="ref-16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conrad</surname><given-names>MD</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>PJ</given-names></name></person-group>:
<article-title>Antimalarial drug resistance in Africa: the calm before the storm?</article-title><source><italic toggle="yes">Lancet Infect Dis.</italic></source><year>2019</year>;<volume>19</volume>(<issue>10</issue>):<fpage>e338</fpage>&#8211;<lpage>e351</lpage>.
<pub-id pub-id-type="doi">10.1016/S1473-3099(19)30261-0</pub-id><pub-id pub-id-type="pmid">31375467</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/736337650">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deutsch-Feldman</surname><given-names>M</given-names></name><name name-style="western"><surname>Aydemir</surname><given-names>O</given-names></name><name name-style="western"><surname>Carrel</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>The changing landscape of
<italic toggle="yes">Plasmodium falciparum</italic> drug resistance in the Democratic Republic of Congo.</article-title><source><italic toggle="yes">BMC Infect Dis.</italic></source><year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>872</fpage>.
<pub-id pub-id-type="doi">10.1186/s12879-019-4523-0</pub-id><pub-id pub-id-type="pmid">31640574</pub-id><pub-id pub-id-type="pmcid">PMC6805465</pub-id></mixed-citation></ref><ref id="ref-18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balikagala</surname><given-names>B</given-names></name><name name-style="western"><surname>Mita</surname><given-names>T</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Absence of
<italic toggle="yes">in vivo</italic> selection for K13 mutations after artemether&#8211;lumefantrine treatment in Uganda.</article-title><source><italic toggle="yes">Malar J.</italic></source><year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>23</fpage>.
<pub-id pub-id-type="doi">10.1186/s12936-016-1663-1</pub-id><pub-id pub-id-type="pmid">28068997</pub-id><pub-id pub-id-type="pmcid">PMC5223472</pub-id></mixed-citation></ref><ref id="ref-19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mustapha</surname><given-names>MM</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LH</given-names></name></person-group>:
<article-title>Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.</article-title><source><italic toggle="yes">Hum Vaccin Immunother.</italic></source><year>2018</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1107</fpage>&#8211;<lpage>1115</lpage>.
<pub-id pub-id-type="doi">10.1080/21645515.2017.1412020</pub-id><pub-id pub-id-type="pmid">29211624</pub-id><pub-id pub-id-type="pmcid">PMC5989898</pub-id></mixed-citation></ref><ref id="ref-20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>MOC</given-names></name><name name-style="western"><surname>Odutola</surname><given-names>AA</given-names></name><name name-style="western"><surname>Owiafe</surname><given-names>PK</given-names></name><etal/></person-group>:
<article-title>Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants.</article-title><source><italic toggle="yes">Sci Transl Med.</italic></source><year>2011</year>;<volume>3</volume>(<issue>88</issue>):<fpage>88ra56</fpage>.
<pub-id pub-id-type="doi">10.1126/scitranslmed.3002461</pub-id><pub-id pub-id-type="pmid">21697532</pub-id></mixed-citation></ref><ref id="ref-21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mensah</surname><given-names>VA</given-names></name><name name-style="western"><surname>Roetynck</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanteh</surname><given-names>EK</given-names></name><etal/></person-group>:
<article-title>Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial.</article-title><source><italic toggle="yes">Front Immunol.</italic></source><year>2017</year>;<volume>8</volume>:<fpage>1551</fpage>.
<pub-id pub-id-type="doi">10.3389/fimmu.2017.01551</pub-id><pub-id pub-id-type="pmid">29213269</pub-id><pub-id pub-id-type="pmcid">PMC5702785</pub-id></mixed-citation></ref><ref id="ref-22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doba&#241;o</surname><given-names>C</given-names></name><name name-style="western"><surname>Ubillos</surname><given-names>I</given-names></name><name name-style="western"><surname>Jairoce</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated
<italic toggle="yes">Plasmodium falciparum</italic> antigens associated with protection against clinical malaria in African children: a case-control study.</article-title><source><italic toggle="yes">BMC Med.</italic></source><year>2019</year>;<volume>17</volume>(<issue>1</issue>):<fpage>157</fpage>.
<pub-id pub-id-type="doi">10.1186/s12916-019-1378-6</pub-id><pub-id pub-id-type="pmid">31409398</pub-id><pub-id pub-id-type="pmcid">PMC6693200</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/736423511">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerra Mendoza</surname><given-names>Y</given-names></name><name name-style="western"><surname>Garric</surname><given-names>E</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.</article-title><source><italic toggle="yes">Hum Vaccin Immunother.</italic></source><year>2019</year>;<volume>15</volume>(<issue>10</issue>):<fpage>2386</fpage>&#8211;<lpage>2398</lpage>.
<pub-id pub-id-type="doi">10.1080/21645515.2019.1586040</pub-id><pub-id pub-id-type="pmid">31012786</pub-id><pub-id pub-id-type="pmcid">PMC6816384</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/735603359">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galactionova</surname><given-names>K</given-names></name><name name-style="western"><surname>Tediosi</surname><given-names>F</given-names></name><name name-style="western"><surname>Camponovo</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.</article-title><source><italic toggle="yes">Vaccine.</italic></source><year>2017</year>;<volume>35</volume>(<issue>1</issue>):<fpage>53</fpage>&#8211;<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.042</pub-id><pub-id pub-id-type="pmid">27890400</pub-id></mixed-citation></ref><ref id="ref-25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>SL</given-names></name><name name-style="western"><surname>Shann</surname><given-names>F</given-names></name><name name-style="western"><surname>Moss</surname><given-names>WJ</given-names></name><etal/></person-group>:
<article-title>RTS,S Malaria Vaccine and Increased Mortality in Girls.</article-title><source><italic toggle="yes">mBio.</italic></source><year>2016</year>;<volume>7</volume>(<issue>2</issue>):<fpage>e00514</fpage>&#8211;<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1128/mBio.00514-16</pub-id><pub-id pub-id-type="pmid">27118593</pub-id><pub-id pub-id-type="pmcid">PMC4850267</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/726472002">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giefing-Kr&#246;ll</surname><given-names>C</given-names></name><name name-style="western"><surname>Berger</surname><given-names>P</given-names></name><name name-style="western"><surname>Lepperdinger</surname><given-names>G</given-names></name><etal/></person-group>:
<article-title>How sex and age affect immune responses, susceptibility to infections, and response to vaccination.</article-title><source><italic toggle="yes">Aging Cell.</italic></source><year>2015</year>;<volume>14</volume>(<issue>3</issue>):<fpage>309</fpage>&#8211;<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1111/acel.12326</pub-id><pub-id pub-id-type="pmid">25720438</pub-id><pub-id pub-id-type="pmcid">PMC4406660</pub-id></mixed-citation></ref><ref id="ref-27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flanagan</surname><given-names>KL</given-names></name><name name-style="western"><surname>Fink</surname><given-names>AL</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Sex and Gender Differences in the Outcomes of Vaccination over the Life Course.</article-title><source><italic toggle="yes">Annu Rev Cell Dev Biol.</italic></source><year>2017</year>;<volume>33</volume>:<fpage>577</fpage>&#8211;<lpage>599</lpage>.
<pub-id pub-id-type="doi">10.1146/annurev-cellbio-100616-060718</pub-id><pub-id pub-id-type="pmid">28992436</pub-id></mixed-citation></ref><ref id="ref-28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Good</surname><given-names>MF</given-names></name><name name-style="western"><surname>Stanisic</surname><given-names>DI</given-names></name></person-group>:
<article-title>Whole parasite vaccines for the asexual blood stages of Plasmodium.</article-title><source><italic toggle="yes">Immunol Rev.</italic></source><year>2020</year>;<volume>293</volume>(<issue>1</issue>):<fpage>270</fpage>&#8211;<lpage>282</lpage>.
<pub-id pub-id-type="doi">10.1111/imr.12819</pub-id><pub-id pub-id-type="pmid">31709558</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/736891831">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>DH</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>P</given-names></name><name name-style="western"><surname>Bodmer</surname><given-names>JL</given-names></name><etal/></person-group>:
<article-title>Large screen approaches to identify novel malaria vaccine candidates.</article-title><source><italic toggle="yes">Vaccine.</italic></source><year>2015</year>;<volume>33</volume>(<issue>52</issue>):<fpage>7496</fpage>&#8211;<lpage>505</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.059</pub-id><pub-id pub-id-type="pmid">26428458</pub-id><pub-id pub-id-type="pmcid">PMC4729565</pub-id></mixed-citation></ref><ref id="ref-30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swearingen</surname><given-names>KE</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>SE</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Interrogating the
<italic toggle="yes">Plasmodium</italic> Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics.</article-title><source><italic toggle="yes">PLoS Pathog.</italic></source><year>2016</year>;<volume>12</volume>(<issue>4</issue>):<fpage>e1005606</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.ppat.1005606</pub-id><pub-id pub-id-type="pmid">27128092</pub-id><pub-id pub-id-type="pmcid">PMC4851412</pub-id></mixed-citation></ref><ref id="ref-31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bustamante</surname><given-names>LY</given-names></name><name name-style="western"><surname>Powell</surname><given-names>GT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y-C</given-names></name><etal/></person-group>:
<article-title>Synergistic malaria vaccine combinations identified by systematic antigen screening.</article-title><source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source><year>2017</year>;<volume>114</volume>(<issue>45</issue>):<fpage>12045</fpage>&#8211;<lpage>12050</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1702944114</pub-id><pub-id pub-id-type="pmid">29078270</pub-id><pub-id pub-id-type="pmcid">PMC5692528</pub-id></mixed-citation></ref><ref id="ref-32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanoi</surname><given-names>BN</given-names></name><name name-style="western"><surname>Nagaoka</surname><given-names>H</given-names></name><name name-style="western"><surname>Morita</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Comprehensive analysis of antibody responses to
<italic toggle="yes">Plasmodium falciparum</italic> erythrocyte membrane protein 1 domains.</article-title><source><italic toggle="yes">Vaccine.</italic></source><year>2018</year>;<volume>36</volume>(<issue>45</issue>):<fpage>6826</fpage>&#8211;<lpage>6833</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.08.058</pub-id><pub-id pub-id-type="pmid">30262245</pub-id></mixed-citation></ref><ref id="ref-33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yagi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bang</surname><given-names>G</given-names></name><name name-style="western"><surname>Tougan</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>Protective epitopes of the
<italic toggle="yes">Plasmodium falciparum</italic> SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences.</article-title><source><italic toggle="yes">PLoS One.</italic></source><year>2014</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e98460</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0098460</pub-id><pub-id pub-id-type="pmid">24886718</pub-id><pub-id pub-id-type="pmcid">PMC4041889</pub-id></mixed-citation></ref><ref id="ref-34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyen</surname><given-names>D</given-names></name><name name-style="western"><surname>Torres</surname><given-names>JL</given-names></name><name name-style="western"><surname>Wille-Reece</surname><given-names>U</given-names></name><etal/></person-group>:
<article-title>Structural basis for antibody recognition of the NANP repeats in
<italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite protein.</article-title><source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source><year>2017</year>;<volume>114</volume>(<issue>48</issue>):<fpage>E10438</fpage>&#8211;<lpage>E10445</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1715812114</pub-id><pub-id pub-id-type="pmid">29138320</pub-id><pub-id pub-id-type="pmcid">PMC5715787</pub-id></mixed-citation></ref><ref id="ref-35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scally</surname><given-names>SW</given-names></name><name name-style="western"><surname>Murugan</surname><given-names>R</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection.</article-title><source><italic toggle="yes">J Exp Med.</italic></source><year>2018</year>;<volume>215</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1084/jem.20170869</pub-id><pub-id pub-id-type="pmid">29167197</pub-id><pub-id pub-id-type="pmcid">PMC5748854</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/732150119">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doritchamou</surname><given-names>JY</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>R</given-names></name><name name-style="western"><surname>Renn</surname><given-names>JP</given-names></name><etal/></person-group>:
<article-title>Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some
<italic toggle="yes">Plasmodium falciparum</italic> strains.</article-title><source><italic toggle="yes">Commun Biol.</italic></source><year>2019</year>;<volume>2</volume>:<fpage>457</fpage>.
<pub-id pub-id-type="doi">10.1038/s42003-019-0704-z</pub-id><pub-id pub-id-type="pmid">31840102</pub-id><pub-id pub-id-type="pmcid">PMC6897902</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/737042731">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rawlinson</surname><given-names>TA</given-names></name><name name-style="western"><surname>Barber</surname><given-names>NM</given-names></name><name name-style="western"><surname>Mohring</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>Structural basis for inhibition of
<italic toggle="yes">Plasmodium vivax</italic> invasion by a broadly neutralizing vaccine-induced human antibody.</article-title><source><italic toggle="yes">Nat Microbiol.</italic></source><year>2019</year>;<volume>4</volume>(<issue>9</issue>):<fpage>1497</fpage>&#8211;<lpage>507</lpage>.
<pub-id pub-id-type="doi">10.1038/s41564-019-0462-1</pub-id><pub-id pub-id-type="pmid">31133755</pub-id><pub-id pub-id-type="pmcid">PMC6711757</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/736034922">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urusova</surname><given-names>D</given-names></name><name name-style="western"><surname>Carias</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group>:
<article-title>Structural basis for neutralization of
<italic toggle="yes">Plasmodium vivax</italic> by naturally acquired human antibodies that target DBP.</article-title><source><italic toggle="yes">Nat Microbiol.</italic></source><year>2019</year>;<volume>4</volume>(<issue>9</issue>):<fpage>1486</fpage>&#8211;<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1038/s41564-019-0461-2</pub-id><pub-id pub-id-type="pmid">31133752</pub-id><pub-id pub-id-type="pmcid">PMC6707876</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/735842437">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitacre</surname><given-names>DC</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>DA</given-names></name><name name-style="western"><surname>Peters</surname><given-names>CJ</given-names></name><etal/></person-group>:
<article-title>
<italic toggle="yes">P. falciparum</italic> and
<italic toggle="yes">P. vivax</italic> Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections.</article-title><source><italic toggle="yes">PLoS One.</italic></source><year>2015</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e0124856</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0124856</pub-id><pub-id pub-id-type="pmid">25933001</pub-id><pub-id pub-id-type="pmcid">PMC4416889</pub-id></mixed-citation></ref><ref id="ref-40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Rollier</surname><given-names>CS</given-names></name><etal/></person-group>:
<article-title>Viral vectors as vaccine platforms: from immunogenicity to impact.</article-title><source><italic toggle="yes">Curr Opin Immunol.</italic></source><year>2016</year>;<volume>41</volume>:<fpage>47</fpage>&#8211;<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1016/j.coi.2016.05.014</pub-id><pub-id pub-id-type="pmid">27286566</pub-id></mixed-citation></ref><ref id="ref-41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janitzek</surname><given-names>CM</given-names></name><name name-style="western"><surname>Matondo</surname><given-names>S</given-names></name><name name-style="western"><surname>Thrane</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.</article-title><source><italic toggle="yes">Malar J.</italic></source><year>2016</year>;<volume>15</volume>(<issue>1</issue>):<fpage>545</fpage>.
<pub-id pub-id-type="doi">10.1186/s12936-016-1574-1</pub-id><pub-id pub-id-type="pmid">27825348</pub-id><pub-id pub-id-type="pmcid">PMC5101663</pub-id></mixed-citation></ref><ref id="ref-42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yenkoidiok-Douti</surname><given-names>L</given-names></name><name name-style="western"><surname>Williams</surname><given-names>AE</given-names></name><name name-style="western"><surname>Canepa</surname><given-names>GE</given-names></name><etal/></person-group>:
<article-title>Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine.</article-title><source><italic toggle="yes">Sci Rep.</italic></source><year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>16833</fpage>.
<pub-id pub-id-type="doi">10.1038/s41598-019-53208-z</pub-id><pub-id pub-id-type="pmid">31727945</pub-id><pub-id pub-id-type="pmcid">PMC6856133</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/736915903">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janitzek</surname><given-names>CM</given-names></name><name name-style="western"><surname>Peabody</surname><given-names>J</given-names></name><name name-style="western"><surname>Thrane</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine.</article-title><source><italic toggle="yes">Sci Rep.</italic></source><year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>5260</fpage>.
<pub-id pub-id-type="doi">10.1038/s41598-019-41522-5</pub-id><pub-id pub-id-type="pmid">30918267</pub-id><pub-id pub-id-type="pmcid">PMC6437161</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/735412890">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leneghan</surname><given-names>DB</given-names></name><name name-style="western"><surname>Miura</surname><given-names>K</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>IJ</given-names></name><etal/></person-group>:
<article-title>Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.</article-title><source><italic toggle="yes">Sci Rep.</italic></source><year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>3811</fpage>.
<pub-id pub-id-type="doi">10.1038/s41598-017-03798-3</pub-id><pub-id pub-id-type="pmid">28630474</pub-id><pub-id pub-id-type="pmcid">PMC5476561</pub-id></mixed-citation></ref><ref id="ref-45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></name></person-group>:
<article-title>Vaccines: correlates of vaccine-induced immunity.</article-title><source><italic toggle="yes">Clin Infect Dis.</italic></source><year>2008</year>;<volume>47</volume>(<issue>3</issue>):<fpage>401</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1086/589862</pub-id><pub-id pub-id-type="pmid">18558875</pub-id></mixed-citation></ref><ref id="ref-46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Els</surname><given-names>C</given-names></name><name name-style="western"><surname>Mjaaland</surname><given-names>S</given-names></name><name name-style="western"><surname>N&#230;ss</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Fast vaccine design and development based on correlates of protection (COPs).</article-title><source><italic toggle="yes">Hum Vaccin Immunother.</italic></source><year>2014</year>;<volume>10</volume>(<issue>7</issue>):<fpage>1935</fpage>&#8211;<lpage>48</lpage>.
<pub-id pub-id-type="doi">10.4161/hv.28639</pub-id><pub-id pub-id-type="pmid">25424803</pub-id><pub-id pub-id-type="pmcid">PMC4186026</pub-id></mixed-citation></ref><ref id="ref-47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMahon</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Dentinger</surname><given-names>CM</given-names></name><name name-style="western"><surname>Bruden</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose.</article-title><source><italic toggle="yes">J Infect Dis.</italic></source><year>2009</year>;<volume>200</volume>(<issue>9</issue>):<fpage>1390</fpage>&#8211;<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1086/606119</pub-id><pub-id pub-id-type="pmid">19785526</pub-id></mixed-citation></ref><ref id="ref-48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>QY</given-names></name><etal/></person-group>:
<article-title>Long-term effectiveness of plasma-derived hepatitis B vaccine 22-28 years after immunization in a hepatitis B virus endemic rural area: is an adult booster dose needed?</article-title><source><italic toggle="yes">Epidemiol Infect.</italic></source><year>2017</year>;<volume>145</volume>(<issue>5</issue>):<fpage>887</fpage>&#8211;<lpage>94</lpage>.
<pub-id pub-id-type="doi">10.1017/S0950268816003046</pub-id><pub-id pub-id-type="pmid">28065199</pub-id><pub-id pub-id-type="pmcid">PMC9507816</pub-id></mixed-citation></ref><ref id="ref-49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simons</surname><given-names>BC</given-names></name><name name-style="western"><surname>Spradling</surname><given-names>PR</given-names></name><name name-style="western"><surname>Bruden</surname><given-names>DJ</given-names></name><etal/></person-group>:
<article-title>A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.</article-title><source><italic toggle="yes">J Infect Dis.</italic></source><year>2016</year>;<volume>214</volume>(<issue>2</issue>):<fpage>273</fpage>&#8211;<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiw142</pub-id><pub-id pub-id-type="pmid">27056956</pub-id><pub-id pub-id-type="pmcid">PMC4918827</pub-id></mixed-citation></ref><ref id="ref-50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>KM</given-names></name><name name-style="western"><surname>Okitsu</surname><given-names>S</given-names></name><name name-style="western"><surname>Porter</surname><given-names>DW</given-names></name><etal/></person-group>:
<article-title>Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships.</article-title><source><italic toggle="yes">Immunology.</italic></source><year>2015</year>;<volume>145</volume>(<issue>1</issue>):<fpage>71</fpage>&#8211;<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.1111/imm.12428</pub-id><pub-id pub-id-type="pmid">25471322</pub-id><pub-id pub-id-type="pmcid">PMC4405325</pub-id></mixed-citation></ref><ref id="ref-51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>MT</given-names></name><name name-style="western"><surname>Verity</surname><given-names>R</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>JT</given-names></name><etal/></person-group>:
<article-title>Immunogenicity of the RTS,S/AS01 Malaria Vaccine and Implications for Duration of Vaccine Efficacy: Secondary Analysis of Data From a Phase 3 Randomised Controlled Trial.</article-title><source><italic toggle="yes">Lancet Infect Dis.</italic></source><year>2015</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1450</fpage>&#8211;<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/S1473-3099(15)00239-X</pub-id><pub-id pub-id-type="pmid">26342424</pub-id><pub-id pub-id-type="pmcid">PMC4655306</pub-id></mixed-citation></ref><ref id="ref-52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regules</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cicatelli</surname><given-names>SB</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>JW</given-names></name><etal/></person-group>:
<article-title>Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.</article-title><source><italic toggle="yes">J Infect Dis.</italic></source><year>2016</year>;<volume>214</volume>(<issue>5</issue>):<fpage>762</fpage>&#8211;<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1093/infdis/jiw237</pub-id><pub-id pub-id-type="pmid">27296848</pub-id></mixed-citation></ref><ref id="ref-53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Regules</surname><given-names>JA</given-names></name><name name-style="western"><surname>Darko</surname><given-names>CA</given-names></name><etal/></person-group>:
<article-title>Delayed Fractional Dose Regimen of the RTS,S/AS01 Malaria Vaccine Candidate Enhances an IgG4 Response That Inhibits Serum Opsonophagocytosis.</article-title><source><italic toggle="yes">Sci Rep.</italic></source><year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>7998</fpage>.
<pub-id pub-id-type="doi">10.1038/s41598-017-08526-5</pub-id><pub-id pub-id-type="pmid">28801554</pub-id><pub-id pub-id-type="pmcid">PMC5554171</pub-id></mixed-citation></ref><ref id="ref-54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>MT</given-names></name><name name-style="western"><surname>Bejon</surname><given-names>P</given-names></name><name name-style="western"><surname>Olotu</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>The Relationship Between RTS,S Vaccine-Induced Antibodies, CD4
<sup>+</sup> T Cell Responses and Protection Against
<italic toggle="yes">Plasmodium Falciparum</italic> Infection.</article-title><source><italic toggle="yes">PLoS One.</italic></source><year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e61395</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0061395</pub-id><pub-id pub-id-type="pmid">23613845</pub-id><pub-id pub-id-type="pmcid">PMC3628884</pub-id></mixed-citation></ref><ref id="ref-55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moris</surname><given-names>P</given-names></name><name name-style="western"><surname>Jongert</surname><given-names>E</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>RG</given-names></name></person-group>:
<article-title>Characterization of T-cell Immune Responses in Clinical Trials of the Candidate RTS,S Malaria Vaccine.</article-title><source><italic toggle="yes">Hum Vaccin Immunother.</italic></source><year>2018</year>;<volume>14</volume>(<issue>1</issue>):<fpage>17</fpage>&#8211;<lpage>27</lpage>.
<pub-id pub-id-type="doi">10.1080/21645515.2017.1381809</pub-id><pub-id pub-id-type="pmid">28934066</pub-id><pub-id pub-id-type="pmcid">PMC5791571</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/731253673">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jongo</surname><given-names>SA</given-names></name><name name-style="western"><surname>Church</surname><given-names>LWP</given-names></name><name name-style="western"><surname>Mtoro</surname><given-names>AT</given-names></name><etal/></person-group>:
<article-title>Safety and Differential Antibody and T-Cell Responses to the
<italic toggle="yes">Plasmodium falciparum</italic> Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.</article-title><source><italic toggle="yes">Am J Trop Med Hyg.</italic></source><year>2019</year>;<volume>100</volume>(<issue>6</issue>):<fpage>1433</fpage>&#8211;<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.18-0835</pub-id><pub-id pub-id-type="pmid">30994090</pub-id><pub-id pub-id-type="pmcid">PMC6553883</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/735573538">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theisen</surname><given-names>M</given-names></name><name name-style="western"><surname>Adu</surname><given-names>B</given-names></name><name name-style="western"><surname>Mordm&#252;ller</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>The GMZ2 Malaria Vaccine: From Concept to Efficacy in Humans.</article-title><source><italic toggle="yes">Expert Rev Vaccines.</italic></source><year>2017</year>;<volume>16</volume>(<issue>9</issue>):<fpage>907</fpage>&#8211;<lpage>17</lpage>.
<pub-id pub-id-type="doi">10.1080/14760584.2017.1355246</pub-id><pub-id pub-id-type="pmid">28699823</pub-id></mixed-citation></ref><ref id="ref-58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>EH</given-names></name><name name-style="western"><surname>Atre</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>Combining Immunoprofiling With Machine Learning to Assess the Effects of Adjuvant Formulation on Human Vaccine-Induced Immunity.</article-title><source><italic toggle="yes">Hum Vaccin Immunother.</italic></source><year>2020</year>;<volume>16</volume>(<issue>2</issue>):<fpage>400</fpage>&#8211;<lpage>11</lpage>.
<pub-id pub-id-type="doi">10.1080/21645515.2019.1654807</pub-id><pub-id pub-id-type="pmid">31589550</pub-id><pub-id pub-id-type="pmcid">PMC7062453</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/736721309">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazmin</surname><given-names>D</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EK</given-names></name><etal/></person-group>:
<article-title>Systems Analysis of Protective Immune Responses to RTS,S Malaria Vaccination in Humans.</article-title><source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source><year>2017</year>;<volume>114</volume>(<issue>9</issue>):<fpage>2425</fpage>&#8211;<lpage>30</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1621489114</pub-id><pub-id pub-id-type="pmid">28193898</pub-id><pub-id pub-id-type="pmcid">PMC5338562</pub-id></mixed-citation></ref><ref id="ref-60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIntosh</surname><given-names>EDG</given-names></name><name name-style="western"><surname>Br&#246;ker</surname><given-names>M</given-names></name><name name-style="western"><surname>Wassil</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Serum Bactericidal Antibody Assays - The Role of Complement in Infection and Immunity.</article-title><source><italic toggle="yes">Vaccine.</italic></source><year>2015</year>;<volume>33</volume>(<issue>36</issue>):<fpage>4414</fpage>&#8211;<lpage>21</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.019</pub-id><pub-id pub-id-type="pmid">26187262</pub-id></mixed-citation></ref><ref id="ref-61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosley</surname><given-names>JF</given-names></name><name name-style="western"><surname>Smith</surname><given-names>LL</given-names></name><name name-style="western"><surname>Brantley</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>Vaxchora: The First FDA-Approved Cholera Vaccination in the United States.</article-title><source><italic toggle="yes">P T.</italic></source><year>2017</year>;<volume>42</volume>(<issue>10</issue>):<fpage>638</fpage>&#8211;<lpage>40</lpage>.

<pub-id pub-id-type="pmid">29018300</pub-id><pub-id pub-id-type="pmcid">PMC5614415</pub-id></mixed-citation></ref><ref id="ref-62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saluja</surname><given-names>T</given-names></name><name name-style="western"><surname>Mogasale</surname><given-names>VV</given-names></name><name name-style="western"><surname>Excler</surname><given-names>JL</given-names></name><etal/></person-group>:
<article-title>An overview of Vaxchora
<sup>TM</sup>, a live attenuated oral cholera vaccine.</article-title><source><italic toggle="yes">Hum Vaccin Immunother.</italic></source><year>2020</year>;<volume>16</volume>(<issue>1</issue>):<fpage>42</fpage>&#8211;<lpage>50</lpage>.
<pub-id pub-id-type="doi">10.1080/21645515.2019.1644882</pub-id><pub-id pub-id-type="pmid">31339792</pub-id><pub-id pub-id-type="pmcid">PMC7012186</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/737698123">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roestenberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamerling</surname><given-names>IMC</given-names></name><name name-style="western"><surname>de Visser</surname><given-names>SJ</given-names></name></person-group>:
<article-title>Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development.</article-title><source><italic toggle="yes">Front Med (Lausanne).</italic></source><year>2018</year>;<volume>5</volume>:<fpage>297</fpage>.
<pub-id pub-id-type="doi">10.3389/fmed.2018.00297</pub-id><pub-id pub-id-type="pmid">30420951</pub-id><pub-id pub-id-type="pmcid">PMC6215823</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/734512379">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanisic</surname><given-names>DI</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>JS</given-names></name><name name-style="western"><surname>Good</surname><given-names>MF</given-names></name></person-group>:
<article-title>Controlled Human Malaria Infection: Applications, Advances, and Challenges.</article-title><source><italic toggle="yes">Infect Immun.</italic></source><year>2018</year>;<volume>86</volume>(<issue>1</issue>): pii: e00479-17.
<pub-id pub-id-type="doi">10.1128/IAI.00479-17</pub-id><pub-id pub-id-type="pmid">28923897</pub-id><pub-id pub-id-type="pmcid">PMC5736798</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/731246289">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>KA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Adams</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.</article-title><source><italic toggle="yes">J Clin Invest.</italic></source><year>2018</year>;<volume>128</volume>(<issue>4</issue>):<fpage>1551</fpage>&#8211;<lpage>1562</lpage>.
<pub-id pub-id-type="doi">10.1172/JCI98012</pub-id><pub-id pub-id-type="pmid">29389671</pub-id><pub-id pub-id-type="pmcid">PMC5873858</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/732592221">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mordm&#252;ller</surname><given-names>B</given-names></name><name name-style="western"><surname>Surat</surname><given-names>G</given-names></name><name name-style="western"><surname>Lagler</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.</article-title><source><italic toggle="yes">Nature.</italic></source><year>2017</year>;<volume>542</volume>(<issue>7642</issue>):<fpage>445</fpage>&#8211;<lpage>449</lpage>.
<pub-id pub-id-type="doi">10.1038/nature21060</pub-id><pub-id pub-id-type="pmid">28199305</pub-id><pub-id pub-id-type="pmcid">PMC10906480</pub-id></mixed-citation></ref><ref id="ref-67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schats</surname><given-names>R</given-names></name><name name-style="western"><surname>Bijker</surname><given-names>EM</given-names></name><name name-style="western"><surname>van Gemert</surname><given-names>GJ</given-names></name><etal/></person-group>:
<article-title>Heterologous Protection against Malaria after Immunization with
<italic toggle="yes">Plasmodium falciparum</italic> Sporozoites.</article-title><source><italic toggle="yes">PLoS One.</italic></source><year>2015</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e0124243</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0124243</pub-id><pub-id pub-id-type="pmid">25933168</pub-id><pub-id pub-id-type="pmcid">PMC4416703</pub-id></mixed-citation></ref><ref id="ref-68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>AS</given-names></name><name name-style="western"><surname>Berry</surname><given-names>AA</given-names></name><etal/></person-group>:
<article-title>Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.</article-title><source><italic toggle="yes">Proc Natl Acad Sci U S A.</italic></source><year>2017</year>;<volume>114</volume>(<issue>10</issue>):<fpage>2711</fpage>&#8211;<lpage>2716</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.1615324114</pub-id><pub-id pub-id-type="pmid">28223498</pub-id><pub-id pub-id-type="pmcid">PMC5347610</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/727331397">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ar&#233;valo-Herrera</surname><given-names>M</given-names></name><name name-style="western"><surname>V&#225;squez-Jim&#233;nez</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lopez-Perez</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Protective Efficacy of
<italic toggle="yes">Plasmodium vivax</italic> Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial.</article-title><source><italic toggle="yes">PLoS Negl Trop Dis.</italic></source><year>2016</year>;<volume>10</volume>(<issue>10</issue>):<fpage>e0005070</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pntd.0005070</pub-id><pub-id pub-id-type="pmid">27760143</pub-id><pub-id pub-id-type="pmcid">PMC5070852</pub-id></mixed-citation></ref><ref id="ref-70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Hoogen</surname><given-names>LL</given-names></name><name name-style="western"><surname>Walk</surname><given-names>J</given-names></name><name name-style="western"><surname>Oulton</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human
<italic toggle="yes">Plasmodium falciparum</italic> Infections.</article-title><source><italic toggle="yes">Front Microbiol.</italic></source><year>2019</year>;<volume>9</volume>:<fpage>3300</fpage>.
<pub-id pub-id-type="doi">10.3389/fmicb.2018.03300</pub-id><pub-id pub-id-type="pmid">30700984</pub-id><pub-id pub-id-type="pmcid">PMC6343524</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/734959174">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dejon-Agobe</surname><given-names>JC</given-names></name><name name-style="western"><surname>Ateba-Ngoa</surname><given-names>U</given-names></name><name name-style="western"><surname>Lalremruata</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.</article-title><source><italic toggle="yes">Clin Infect Dis.</italic></source><year>2019</year>;<volume>69</volume>(<issue>8</issue>):<fpage>1377</fpage>&#8211;<lpage>84</lpage>.
<pub-id pub-id-type="doi">10.1093/cid/ciy1087</pub-id><pub-id pub-id-type="pmid">30561539</pub-id><pub-id pub-id-type="pmcid">PMC6763635</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/734655648">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCall</surname><given-names>MBB</given-names></name><name name-style="western"><surname>Wammes</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Langenberg</surname><given-names>MC</given-names></name><etal/></person-group>:
<article-title>Infectivity of
<italic toggle="yes">Plasmodium falciparum</italic> sporozoites determines emerging parasitemia in infected volunteers.</article-title><source><italic toggle="yes">Sci Transl Med.</italic></source><year>2017</year>;<volume>9</volume>(<issue>395</issue>): pii: eaag2490.
<pub-id pub-id-type="doi">10.1126/scitranslmed.aag2490</pub-id><pub-id pub-id-type="pmid">28637923</pub-id></mixed-citation></ref><ref id="ref-73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walk</surname><given-names>J</given-names></name><name name-style="western"><surname>Reuling</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Behet</surname><given-names>MC</given-names></name><etal/></person-group>:
<article-title>Modest heterologous protection after
<italic toggle="yes">Plasmodium falciparum</italic> sporozoite immunization: a double-blind randomized controlled clinical trial.</article-title><source><italic toggle="yes">BMC Med.</italic></source><year>2017</year>;<volume>15</volume>(<issue>1</issue>):<fpage>168</fpage>.
<pub-id pub-id-type="doi">10.1186/s12916-017-0923-4</pub-id><pub-id pub-id-type="pmid">28903777</pub-id><pub-id pub-id-type="pmcid">PMC5598044</pub-id></mixed-citation></ref><ref id="ref-74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langenberg</surname><given-names>MCC</given-names></name><name name-style="western"><surname>Wammes</surname><given-names>LJ</given-names></name><name name-style="western"><surname>McCall</surname><given-names>MBB</given-names></name><etal/></person-group>:
<article-title>Controlled Human Malaria Infection with Graded Numbers of
<italic toggle="yes">Plasmodium falciparum</italic> NF135.C10- or NF166.C8-Infected Mosquitoes.</article-title><source><italic toggle="yes">Am J Trop Med Hyg.</italic></source><year>2018</year>;<volume>99</volume>(<issue>3</issue>):<fpage>709</fpage>&#8211;<lpage>12</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.18-0194</pub-id><pub-id pub-id-type="pmid">30014816</pub-id><pub-id pub-id-type="pmcid">PMC6169176</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/733652328">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>KA</given-names></name><name name-style="western"><surname>Dr&#225;bek</surname><given-names>EF</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Strains used in whole organism
<italic toggle="yes">Plasmodium falciparum</italic> vaccine trials differ in genome structure, sequence, and immunogenic potential.</article-title><source><italic toggle="yes">Genome Med.</italic></source><year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>6</fpage>.
<pub-id pub-id-type="doi">10.1186/s13073-019-0708-9</pub-id><pub-id pub-id-type="pmid">31915075</pub-id><pub-id pub-id-type="pmcid">PMC6950926</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/737181356">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chattopadhyay</surname><given-names>R</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>D</given-names></name></person-group>:
<article-title>Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food &amp; drug administration (FDA) perspective.</article-title><source><italic toggle="yes">Vaccine.</italic></source><year>2017</year>;<volume>35</volume>(<issue>21</issue>):<fpage>2767</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.072</pub-id><pub-id pub-id-type="pmid">28431816</pub-id></mixed-citation></ref><ref id="ref-77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Good</surname><given-names>MF</given-names></name><name name-style="western"><surname>Miller</surname><given-names>LH</given-names></name></person-group>:
<article-title>Interpreting challenge data from early phase malaria blood stage vaccine trials.</article-title><source><italic toggle="yes">Expert Rev Vaccines.</italic></source><year>2018</year>;<volume>17</volume>(<issue>3</issue>):<fpage>189</fpage>&#8211;<lpage>96</lpage>.
<pub-id pub-id-type="doi">10.1080/14760584.2018.1435278</pub-id><pub-id pub-id-type="pmid">29382292</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/732587837">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Connor</surname><given-names>D</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>EA</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><etal/></person-group>:
<article-title>High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.</article-title><source><italic toggle="yes">Genome Med.</italic></source><year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>11</fpage>.
<pub-id pub-id-type="doi">10.1186/s13073-017-0400-x</pub-id><pub-id pub-id-type="pmid">28137280</pub-id><pub-id pub-id-type="pmcid">PMC5282650</pub-id></mixed-citation></ref><ref id="ref-79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palacpac</surname><given-names>NMQ</given-names></name><name name-style="western"><surname>Ntege</surname><given-names>E</given-names></name><name name-style="western"><surname>Yeka</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.</article-title><source><italic toggle="yes">PLoS One.</italic></source><year>2013</year>;<volume>8</volume>(<issue>5</issue>):<fpage>e64073</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0064073</pub-id><pub-id pub-id-type="pmid">23724021</pub-id><pub-id pub-id-type="pmcid">PMC3665850</pub-id></mixed-citation></ref><ref id="ref-80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ademolue</surname><given-names>TW</given-names></name><name name-style="western"><surname>Awandare</surname><given-names>GA</given-names></name></person-group>:
<article-title>Evaluating antidisease immunity to malaria and implications for vaccine design.</article-title><source><italic toggle="yes">Immunology.</italic></source><year>2018</year>;<volume>153</volume>(<issue>4</issue>):<fpage>423</fpage>&#8211;<lpage>34</lpage>.
<pub-id pub-id-type="doi">10.1111/imm.12877</pub-id><pub-id pub-id-type="pmid">29211303</pub-id><pub-id pub-id-type="pmcid">PMC5838420</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/732235071">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olotu</surname><given-names>A</given-names></name><name name-style="western"><surname>Urbano</surname><given-names>V</given-names></name><name name-style="western"><surname>Hamad</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men.</article-title><source><italic toggle="yes">Am J Trop Med Hyg.</italic></source><year>2018</year>;<volume>98</volume>(<issue>1</issue>):<fpage>308</fpage>&#8211;<lpage>18</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.17-0449</pub-id><pub-id pub-id-type="pmid">29141739</pub-id><pub-id pub-id-type="pmcid">PMC5928718</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/732122956">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanks</surname><given-names>GD</given-names></name></person-group>:
<article-title>Tolerance May Be More Appropriate Than Immunity When Describing Chronic Malaria Infections.</article-title><source><italic toggle="yes">Am J Trop Med Hyg.</italic></source><year>2019</year>;<volume>100</volume>(<issue>3</issue>):<fpage>497</fpage>&#8211;<lpage>500</lpage>.
<pub-id pub-id-type="doi">10.4269/ajtmh.18-0906</pub-id><pub-id pub-id-type="pmid">30675843</pub-id><pub-id pub-id-type="pmcid">PMC6402920</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/734916549">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yagi</surname><given-names>M</given-names></name><name name-style="western"><surname>Palacpac</surname><given-names>NMQ</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda.</article-title><source><italic toggle="yes">Sci Rep.</italic></source><year>2016</year>;<volume>6</volume>:<fpage>34363</fpage>.
<pub-id pub-id-type="doi">10.1038/srep34363</pub-id><pub-id pub-id-type="pmid">27703240</pub-id><pub-id pub-id-type="pmcid">PMC5050508</pub-id></mixed-citation></ref><ref id="ref-84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dicko</surname><given-names>A</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>B</given-names></name></person-group>:
<article-title>Malaria vaccination and rebound malaria.</article-title><source><italic toggle="yes">Lancet Infect Dis.</italic></source><year>2019</year>;<volume>19</volume>(<issue>8</issue>):<fpage>790</fpage>&#8211;<lpage>1</lpage>.
<pub-id pub-id-type="doi">10.1016/S1473-3099(19)30282-8</pub-id><pub-id pub-id-type="pmid">31300332</pub-id></mixed-citation></ref><ref id="ref-85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tinto</surname><given-names>H</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>W</given-names></name><name name-style="western"><surname>Gesase</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.</article-title><source><italic toggle="yes">Lancet Infect Dis.</italic></source><year>2019</year>;<volume>19</volume>(<issue>8</issue>):<fpage>821</fpage>&#8211;<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1016/S1473-3099(19)30300-7</pub-id><pub-id pub-id-type="pmid">31300331</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/736190761">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olotu</surname><given-names>A</given-names></name><name name-style="western"><surname>Fegan</surname><given-names>G</given-names></name><name name-style="western"><surname>Wambua</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.</article-title><source><italic toggle="yes">N Engl J Med.</italic></source><year>2016</year>;<volume>374</volume>(<issue>26</issue>):<fpage>2519</fpage>&#8211;<lpage>29</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1515257</pub-id><pub-id pub-id-type="pmid">27355532</pub-id><pub-id pub-id-type="pmcid">PMC4962898</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/726470484">F1000 Recommendation</ext-link>
</p></note></ref><ref id="ref-87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palacpac</surname><given-names>NMQ</given-names></name><name name-style="western"><surname>Tougan</surname><given-names>T</given-names></name><name name-style="western"><surname>Horii</surname><given-names>T</given-names></name></person-group>:
<article-title>Preclinical Studies on a New Vaccine Formulation of BK-SE36, a Malaria Vaccine Candidate.</article-title><source><italic toggle="yes">Juntendo Medical Journal.</italic></source><year>2015</year>;<volume>61</volume>(<issue>4</issue>):<fpage>360</fpage>&#8211;<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.14789/jmj.61.360</pub-id></mixed-citation></ref><ref id="ref-88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name><name name-style="western"><surname>Laup&#232;ze</surname><given-names>B</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Adjuvant system AS01: helping to overcome the challenges of modern vaccines.</article-title><source><italic toggle="yes">Expert Rev Vaccines.</italic></source><year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1080/14760584.2016.1213632</pub-id><pub-id pub-id-type="pmid">27448771</pub-id></mixed-citation></ref><ref id="ref-89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>SK</given-names></name><name name-style="western"><surname>Thrane</surname><given-names>S</given-names></name><name name-style="western"><surname>Janitzek</surname><given-names>CM</given-names></name><etal/></person-group>:
<article-title>Improving the malaria transmission-blocking activity of a
<italic toggle="yes">Plasmodium falciparum</italic> 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.</article-title><source><italic toggle="yes">Vaccine.</italic></source><year>2017</year>;<volume>35</volume>(<issue>30</issue>):<fpage>3726</fpage>&#8211;<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.054</pub-id><pub-id pub-id-type="pmid">28578824</pub-id></mixed-citation></ref><ref id="ref-90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mordm&#252;ller</surname><given-names>B</given-names></name><name name-style="western"><surname>Sulyok</surname><given-names>M</given-names></name><name name-style="western"><surname>Egger-Adam</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria.</article-title><source><italic toggle="yes">Clin Infect Dis.</italic></source><year>2019</year>;<volume>69</volume>(<issue>9</issue>):<fpage>1509</fpage>&#8211;<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1093/cid/ciy1140</pub-id><pub-id pub-id-type="pmid">30629148</pub-id><pub-id pub-id-type="pmcid">PMC6792113</pub-id></mixed-citation><note><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://f1000.com/prime/734840452">F1000 Recommendation</ext-link>
</p></note></ref></ref-list></back></article></pmc-articleset>